|
NOVEN
APPOINTS KAREN FRANK, MD |
BackMiami, FL, June 24,
2002 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the
appointment of Karen A. Frank, MD as its Vice President – Clinical
Research & Regulatory Affairs. Dr. Frank will report to Robert C. Strauss,
Noven's President, CEO & Chairman, and will be responsible for overseeing
Noven's clinical operations and for providing medical and regulatory direction
for the company.
Prior to joining
Noven, Dr. Frank was a member of the clinical research and development
team at Novartis Pharmaceuticals of East Hanover, New Jersey, where she
developed clinical development plans for new chemical entities and provided
oversight of Phase II-IV clinical trials. Previously, she led clinical
science efforts at Roche Group in Basel, Switzerland, and designed and
conducted clinical trials for Monsanto Pharma/GD Searle in Chicago, Illinois.
Before entering the
private sector, Dr. Frank served as a medical officer at the U.S. Food
and Drug Administration's Center for Drug Evaluation & Research in Rockville,
Maryland. At the FDA, Dr. Frank's responsibilities included reviewing
New Drug Applications and Investigational New Drug Applications and addressing
class labeling and advertising issues.
"Dr. Frank joins
Noven's clinical and regulatory group at a very busy and exciting time,"
said Robert Strauss. "We expect to be submitting our New Drug Application
for MethyPatch® on schedule this summer, entering new clinical
trials this year, and monitoring ongoing clinical trials by third parties
for Noven patch products in foreign markets. Karen's experience at the
FDA and with large-scale clinical trial programs on both sides of the
Atlantic will be invaluable to these efforts, and positions her as an
important contributor to the success of Noven's pipeline products."
Dr. Frank earned
her MD from the Johns Hopkins University School of Medicine. After internship
and residency at Washington University School of Medicine, she completed
board certification in internal medicine. She received fellowship training
in drug development in a program sponsored jointly by the U.S. Food and
Drug Administration and Georgetown University School of Medicine. She
earned her BS in chemistry from Wheaton College.
About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading
developer of advanced transdermal drug delivery technologies and prescription
transdermal products. Together with Novartis Pharmaceuticals Corporation,
Noven owns a highly profitable women's health products company called
Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen
transdermal delivery systems (including Vivelle-Dot®, licensed
to Novogyne, and Estradot®, licensed to Novartis Pharma
AG) and combination estrogen/progestin transdermal delivery systems (including
CombiPatch®, licensed to Novogyne, and Estalis®,
licensed to Novartis Pharma AG). With a range of additional products in
development, including MethyPatch®, Noven is committed
to becoming the world's premier developer, manufacturer and marketer of
transdermal drug delivery systems. For additional information on Noven,
visit http://www.noven.com.
This release contains forward-looking statements related to the business of Noven that can be identified by the use of forward-looking terminology such as "expects" and similar words and phrases. Such statements are qualified by and subject to the risks and uncertainties specified in Noven's most recent filings with the Securities and Exchange Commission and in this press release, including the risk that the MethyPatch NDA may not be filed in a timely fashion, that new U.S. clinical trials may not commence on schedule, that clinical trials in foreign markets may be discontinued, and that any given clinical development project may not result in an approved and commercialized product.
Investor &
Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916
Copyright © 2002 Noven Pharmaceuticals, Inc. All rights reserved.